Cancer Research Technology has an impressive range of over 200 oncology-focused projects under development and potentially available for licensing.
The Cancer Research Technology Pioneer Fund (CPF) today has made its first investment in a collaboration with the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, to develop a promising class of drugs called MPS1 inhibitors to treat cancer. Read more ›
© Cancer Research Technology 2013